Search results for: Precision Medicine
Filter search results
OHE Lunchtime Seminar: An Overview of the US National Institutes of Health (NIH) Patient Reported Outcomes Measurement Information System (PROMIS®) and the PROMIS-Preference (PROPr) Scoring System
31 October 2018, 12:00am
OHE Lunchtime Seminar with Janel Hanmer, Assistant Professor of Medicine, University of Pittsburgh Medical Director, UPMC Patient Reported Outcomes Center. The EQ-5D, Health Utilities Index, SF-6D, and the Quality of…
OHE at ISPOR Philadelphia: Presentations and Posters
4 June 2015
…large prevalence diseases? Lessons from hepatitis C – Adrian Towse’s slides Early access to medicines: What is in it for payers? – Adrian Towse’s slides An Analysis of NICE ‘Recommended…
OHE at ISPOR Philadelphia Part 2: Risk Sharing, Medical Breakthroughs, Early Access and Drug Development Costs
12 May 2015
… Moderator: Dana Goldman (University of Southern California). Panelists: Adrian Towse (OHE), Ross Maclean (Precision Health Economics), Thomas Philipson (University of Chicago). This panel will discuss how the financial…
Recommendations for Making Outcome-based Payments a Reality in the NHS: An Application to Cancer Drugs
21 February 2019
…for Future Health Technology Assessments in Oncology. OHE Consulting Report. RePEc. Towse, A. and Garrison, L., 2017. Value assessment in precision cancer medicine. Journal of Cancer Policy, 11, pp.48–53. DOI….
OHE at ISPOR Europe 2: Conceptual and Practical Challenges in Judging Value
29 October 2014
…Husereau, University of Ottawa and UMIT, Joshua J. Carlson (VeriTech Corporation) (IP6, 11 Nov, 10:15–11:15) This panel addresses the implications of assessing the cost-effectiveness of emerging regenerative medicines, including gene…
The challenges and economics of drug development in 2022
1 July 2013
…be radically transformed as “precision” medicine plugs into the specific genetic makeup of both patients and diseases, and is paired with increasingly powerful and convenient diagnostics. 2. Innovation will be…
Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies
8 January 2020
Histology independent therapies, a new class of medicines that target cancer based on specific genomic or molecular alterations of cancer cells rather than tissue of origin, face significant methodological and…
OHE Models Future UK Medicines Spending for the ABPI
3 July 2012
…NHS expenditure on medicines. On 2 July, the ABPI released its projections for UK NHS medicines spending in the years to 2015 based on our model. The results project that…
Published: OHE Study Projecting UK Medicines Expenditure
30 September 2013
This research varies from other analyses in using a product-level, rather than a macro, approach. PharmacoEconomics has just published OHE’s study projecting medicines expenditure in the UK to 2015. (…